British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer
Ovarian cancer survival in the UK lags behind comparable countries. Results from the ongoing National Ovarian Cancer Audit feasibility pilot (OCAFP) show that approximately 1 in 4 women with advanced ovarian cancer (Stage 2, 3, 4 and unstaged cancer) do not receive any anticancer treatment and only...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/2/337 |
| _version_ | 1797444929100709888 |
|---|---|
| author | Sudha Sundar Andy Nordin Jo Morrison Nick Wood Sadaf Ghaem-Maghami Jo Nieto Andrew Phillips John Butler Kevin Burton Rob Gornall Stephen Dobbs Rosalind Glasspool Richard Peevor Jonathan Ledermann Iain McNeish Nithya Ratnavelu Tim Duncan Jonathan Frost Kenneth Lim Agnieszka Michael Elly Brockbank Ketankumar Gajjar Alexandra Taylor Rebecca Bowen Adrian Andreou Raji Ganesan Shibani Nicum Richard Edmondson Richard Clayton Janos Balega Phil Rolland Hilary Maxwell Christina Fotopoulou |
| author_facet | Sudha Sundar Andy Nordin Jo Morrison Nick Wood Sadaf Ghaem-Maghami Jo Nieto Andrew Phillips John Butler Kevin Burton Rob Gornall Stephen Dobbs Rosalind Glasspool Richard Peevor Jonathan Ledermann Iain McNeish Nithya Ratnavelu Tim Duncan Jonathan Frost Kenneth Lim Agnieszka Michael Elly Brockbank Ketankumar Gajjar Alexandra Taylor Rebecca Bowen Adrian Andreou Raji Ganesan Shibani Nicum Richard Edmondson Richard Clayton Janos Balega Phil Rolland Hilary Maxwell Christina Fotopoulou |
| author_sort | Sudha Sundar |
| collection | DOAJ |
| description | Ovarian cancer survival in the UK lags behind comparable countries. Results from the ongoing National Ovarian Cancer Audit feasibility pilot (OCAFP) show that approximately 1 in 4 women with advanced ovarian cancer (Stage 2, 3, 4 and unstaged cancer) do not receive any anticancer treatment and only 51% in England receive international standard of care treatment, i.e., the combination of surgery and chemotherapy. The audit has also demonstrated wide variation in the percentage of women receiving anticancer treatment for advanced ovarian cancer, be it surgery or chemotherapy across the 19 geographical regions for organisation of cancer delivery (Cancer Alliances). Receipt of treatment also correlates with survival: 5 year Cancer survival varies from 28.6% to 49.6% across England. Here, we take a systems wide approach encompassing both diagnostic pathways and cancer treatment, derived from the whole cohort of women with ovarian cancer to set out recommendations and quality performance indicators (QPI). A multidisciplinary panel established by the British Gynaecological Cancer Society carefully identified QPI against criteria: metrics selected were those easily evaluable nationally using routinely available data and where there was a clear evidence base to support interventions. These QPI will be valuable to other taxpayer funded systems with national data collection mechanisms and are to our knowledge the only population level data derived standards in ovarian cancer. We also identify interventions for Best practice and Research recommendations. |
| first_indexed | 2024-03-09T13:18:32Z |
| format | Article |
| id | doaj.art-8196ed148f974bed9f23c4079a7ed8d8 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T13:18:32Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-8196ed148f974bed9f23c4079a7ed8d82023-11-30T21:32:26ZengMDPI AGCancers2072-66942023-01-0115233710.3390/cancers15020337British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian CancerSudha Sundar0Andy Nordin1Jo Morrison2Nick Wood3Sadaf Ghaem-Maghami4Jo Nieto5Andrew Phillips6John Butler7Kevin Burton8Rob Gornall9Stephen Dobbs10Rosalind Glasspool11Richard Peevor12Jonathan Ledermann13Iain McNeish14Nithya Ratnavelu15Tim Duncan16Jonathan Frost17Kenneth Lim18Agnieszka Michael19Elly Brockbank20Ketankumar Gajjar21Alexandra Taylor22Rebecca Bowen23Adrian Andreou24Raji Ganesan25Shibani Nicum26Richard Edmondson27Richard Clayton28Janos Balega29Phil Rolland30Hilary Maxwell31Christina Fotopoulou32Pan Birmingham Gynaecological Cancer Centre, City Hospital and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B152TT, UKEast Kent Hospitals University Foundation NHS Trust, Ethelburt Road, Canterbury CT1 3NG, UKGRACE Centre, Department of Gynaecological Oncology, Musgrove Park Hospital, Somerset NHS Foundation Trust, Taunton TA1 5DA, UKLancashire Teaching Hospitals NHS Foundation Trust, Preston PR7 1PP, UKDepartment of Surgery and Cancer, Imperial College, London W12 0NN, UKNorfolk and Norwich University Hospital, Colney Lane, Norwich NR4 7UY, UKDerby Gynaecological Cancer Centre, University Hospitals of Derby and Burton, Royal Derby Hospital, Uttoxeter Rd., Derby DE22 3NE, UKRoyal Marsden NHS Foundation Trust, London SW3 6JJ, UKGlasgow Royal Infirmary, PRMH Building, Glasgow G4 0SF, UKDepartment Gynaecological Oncology, Cheltenham General Hospital, Gloucestershire Hospitals NHS Foundation Trust, Gloucester GL53 7AN, UKDepartment of Gynaecological Oncology, Belfast City Hospital, Belfast BT9 7AB, UKBeatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde and University of Glasgow, Glasgow G12 0YN, UKConsultant Gynaecological Oncologist, Clinical Lead for Colposcopy & Gynaecological Cancer MDT, Betsi Cadwaladr University Health Board, Bangor LL57 2PW, UKUCL Cancer Institute, University College London and UCL Hospitals, London WC1E 6DD, UKDepartment of Surgery and Cancer, Imperial College, London W12 0NN, UKNorthern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead NE9 6SX, UKNorfolk and Norwich University Hospital, Colney Lane, Norwich NR4 7UY, UKRoyal United Hospitals Bath NHS Foundation Trust, Bath BA1 3NG, UKCardiff and Vale UHB, Cardiff CF14 4XW, UKUniversity of Surrey and Royal Surrey County Hospital, Guildford GU2 7XH, UKRoyal London Hospital, Barts Health NHS Trust, London EC1 1BB, UKNottingham University Hospitals NHS Trust, City Hospital, Nottingham NG5 1PB, UKRoyal Marsden NHS Foundation Trust, London SW3 6JJ, UKRoyal United Hospitals Bath NHS Foundation Trust, Bath BA1 3NG, UKDepartment of Radiology, Royal United Hospitals Bath NHS Foundation Trust, Bath BA1 3NG, UKDepartment of Cellular Pathology, Birmingham Women’s Hospital, Birmingham SY16 4LE, UKUCL Cancer Institute, University College London and UCL Hospitals, London WC1E 6DD, UKDivision of Molecular and Clinical Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and St Mary’s Hospital, Manchester M13 9PL, UKManchester University NHS Foundation Trust, Manchester M13 9WL, UKPan Birmingham Gynaecological Cancer Centre, City Hospital, West Midlands, Birmingham B15 2SQ, UKDepartment Gynaecological Oncology, Cheltenham General Hospital, Gloucestershire Hospitals NHS Foundation Trust, Gloucester GL53 7AN, UKDorset County Hospital NHS Foundation Trust, Dorset DT1 2JY, UKDepartment of Surgery and Cancer, Gynaecologic Oncology, Imperial College London, London W12 0NN, UKOvarian cancer survival in the UK lags behind comparable countries. Results from the ongoing National Ovarian Cancer Audit feasibility pilot (OCAFP) show that approximately 1 in 4 women with advanced ovarian cancer (Stage 2, 3, 4 and unstaged cancer) do not receive any anticancer treatment and only 51% in England receive international standard of care treatment, i.e., the combination of surgery and chemotherapy. The audit has also demonstrated wide variation in the percentage of women receiving anticancer treatment for advanced ovarian cancer, be it surgery or chemotherapy across the 19 geographical regions for organisation of cancer delivery (Cancer Alliances). Receipt of treatment also correlates with survival: 5 year Cancer survival varies from 28.6% to 49.6% across England. Here, we take a systems wide approach encompassing both diagnostic pathways and cancer treatment, derived from the whole cohort of women with ovarian cancer to set out recommendations and quality performance indicators (QPI). A multidisciplinary panel established by the British Gynaecological Cancer Society carefully identified QPI against criteria: metrics selected were those easily evaluable nationally using routinely available data and where there was a clear evidence base to support interventions. These QPI will be valuable to other taxpayer funded systems with national data collection mechanisms and are to our knowledge the only population level data derived standards in ovarian cancer. We also identify interventions for Best practice and Research recommendations.https://www.mdpi.com/2072-6694/15/2/337quality performance indicatorsBritish Gynaecological cancer societyovarian cancerpopulation data |
| spellingShingle | Sudha Sundar Andy Nordin Jo Morrison Nick Wood Sadaf Ghaem-Maghami Jo Nieto Andrew Phillips John Butler Kevin Burton Rob Gornall Stephen Dobbs Rosalind Glasspool Richard Peevor Jonathan Ledermann Iain McNeish Nithya Ratnavelu Tim Duncan Jonathan Frost Kenneth Lim Agnieszka Michael Elly Brockbank Ketankumar Gajjar Alexandra Taylor Rebecca Bowen Adrian Andreou Raji Ganesan Shibani Nicum Richard Edmondson Richard Clayton Janos Balega Phil Rolland Hilary Maxwell Christina Fotopoulou British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer Cancers quality performance indicators British Gynaecological cancer society ovarian cancer population data |
| title | British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer |
| title_full | British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer |
| title_fullStr | British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer |
| title_full_unstemmed | British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer |
| title_short | British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer |
| title_sort | british gynaecological cancer society recommendations for evidence based population data derived quality performance indicators for ovarian cancer |
| topic | quality performance indicators British Gynaecological cancer society ovarian cancer population data |
| url | https://www.mdpi.com/2072-6694/15/2/337 |
| work_keys_str_mv | AT sudhasundar britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT andynordin britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT jomorrison britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT nickwood britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT sadafghaemmaghami britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT jonieto britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT andrewphillips britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT johnbutler britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT kevinburton britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT robgornall britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT stephendobbs britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT rosalindglasspool britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT richardpeevor britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT jonathanledermann britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT iainmcneish britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT nithyaratnavelu britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT timduncan britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT jonathanfrost britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT kennethlim britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT agnieszkamichael britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT ellybrockbank britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT ketankumargajjar britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT alexandrataylor britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT rebeccabowen britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT adrianandreou britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT rajiganesan britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT shibaninicum britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT richardedmondson britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT richardclayton britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT janosbalega britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT philrolland britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT hilarymaxwell britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer AT christinafotopoulou britishgynaecologicalcancersocietyrecommendationsforevidencebasedpopulationdataderivedqualityperformanceindicatorsforovariancancer |